ATX - couldn't believe that they sold it down after this morning's announcement but guess they wanted the gap closed first
ATX announcement this morning - Results from Successful Phase 1 Clinical Trial of AMP945
Unblinded results from Phase 1 trial confirm AMP945 is safe and well tolerated
• Oral dosing achieved plasma concentrations in excess of those required to inhibit focal adhesion kinase (FAK)
• Results support further development of AMP945 in cancer and fibrosis
